On May 18, 2020 Seattle Genetics, Inc. (Nasdaq:SGEN) reported highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate (ADC) technology advances and innovation will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II being held June 22-24, 2020 (Press release, Seattle Genetics, MAY 18, 2020, View Source [SID1234558243]). Registration information to attend the virtual sessions can be found here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We will have a strong presence at the AACR (Free AACR Whitepaper) annual meeting with 12 data presentations highlighting our leadership in antibody-drug conjugate innovation and the depth and potential of our growing oncology pipeline of targeted therapies," said Scott Peterson, Ph.D., Senior Vice President of Research at Seattle Genetics. "Of key importance, a number of presentations will feature advances in our drug linker and payload components of ADCs. Building on our expertise in CD30 targeted therapies, data will be presented from a new CD30-directed ADC that employs our novel camptothecin ADC technology and is being investigated as a potential future treatment option in CD30-expressing lymphomas."

Dr. Peterson added, "In addition to our ADC technologies, we will also be presenting preclinical data highlighting the activity of our HER2 selective tyrosine kinase inhibitor tucatinib in preclinical models of HER2 mutant driven cancers and in the CNS setting. We look forward to sharing these presentations with the community at the second AACR (Free AACR Whitepaper) virtual meeting."

Abstracts can be found at www.aacr.org and include the following poster presentations below.

New ADC Technology Advances

Abstract Title: Novel Framework for Quantifying Synergy in High-Throughput Drug Combination Cytotoxicity Experiments (Abstract #835)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Clinical and Preclinical Precision Medicine: Next-Generation Sequencing, Functional, and Pharmacogenomics

Abstract Title: Discovery of a Tripeptide-Based Camptothecin Drug-Linker for Antibody-Drug Conjugates with Potent Antitumor Activity and a Broad Therapeutic Window (Abstract #2885)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: Characterization of Payload Release from a Novel Camptothecin Drug-Linker (Abstract #2895)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Pipeline Programs

Abstract Title: SGN-CD30C, a New CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti-Tumor Activity and Superior Tolerability in Preclinical Studies (Abstract #2889)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: Utilizing PDX Models to Better Understand Factors that Predict Response to SGN-CD228A, an Antibody-Drug Conjugate (ADC) for Solid Tumors (Abstract #2888)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: SGN-B6A: A New MMAE ADC Targeting Integrin Beta-6 in Multiple Carcinoma Indications (Abstract #2906)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: SEA-CD40 is a Non-Fucosylated Anti-CD40 Antibody with Potent Pharmacodynamic Activity in Preclinical Models and Patients with Advanced Solid Tumors (Abstract #5535)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Immune Response to Therapies 1

Commercial-Stage Programs

Abstract Title: Preclinical Characterization of Tucatinib in HER2-Amplified Xenograft and CNS Implanted Tumors (Abstract #1962)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Small Molecule Therapeutic Agents

Abstract Title: Tucatinib Inhibits Creatinine and Metformin Renal Tubule Secretion but has No Effect on Renal Function (GFR) (Abstract #3015)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Pharmacokinetics / Pharmacodynamics

Abstract Title: Tucatinib Inhibits CYP3A, CYP2C8 and P-gp-Mediated Elimination and is Impacted by CYP2C8 Inhibition in Healthy Volunteers (Abstract #3016)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Pharmacokinetics / Pharmacodynamics

Abstract Title: Tucatinib, a Selective Small Molecule HER2 Inhibitor, is Active in HER2 Mutant Driven Tumors (Abstract #4222)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Tyrosine Kinase and Phosphatase Inhibitors

Abstract Title: Enfortumab Vedotin, an Anti-Nectin-4 ADC Demonstrates Bystander Cell Killing and Immunogenic Cell Death Anti-Tumor Activity Mechanisms of Action in Urotherlial Cancers (Abstract #5581)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Immunotherapy